Vertex CF data positive, says RBC Capital

theflyonthewall.com

RBC Capital believes that data on Vertex's CF drug looked good and lowers the risk of the treatment. The firm expects the company to report good Phase III results for the drug in summer 2014, and it reiterates an Outperform rating on the stock.

View Comments (0)